Product information and disease descriptionProduct descriptionProduct informationDosing and administration
Dosage
3 evidence topics · 3 sources
Phase 3 regimen in tumor hyperinsulinism
Initiation, escalation, and de-escalation under expanded access
“After exploratory dose-ranging in the first 2 participants, the initiation dose regimen was standardized in subsequent participants to 9 mg/kg weekly, followed by de-escalation as indicated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One participant required escalation from 9 to 12 mg/kg every other week.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Glycemic stabilization was achieved across dosing regimens, with a more pronounced response observed in individuals initiated at 9 mg/kg weekly.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“More protracted responses to ersodetug and longer times to hospital discharge in initially treated individuals were associated with lower starting doses and less frequent administration of ersodetug (6 mg/kg and/or biweekly administration).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote